Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma.

circulating tumor cells liquid biopsy pilot study uveal melanoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
20 Jun 2019
Historique:
received: 11 05 2019
revised: 07 06 2019
accepted: 18 06 2019
entrez: 23 6 2019
pubmed: 23 6 2019
medline: 23 6 2019
Statut: epublish

Résumé

Nearly 50% of uveal melanoma (UM) patients develop metastatic disease, and there remains no current standard assay for detection of minimal residual disease. We conducted a pilot study to check the feasibility of circulating tumor cell (CTC) detection in UM. We enrolled 40 patients with early or metastatic UM of which 20 patients had early-stage disease, 19 had metastatic disease, and one was not evaluable. At initial blood draw, 36% of patients had detectable CTCs (30% in early-stage vs. 42% in metastatic), which increased to 54% at data cutoff (40% in early-stage vs. 68% in metastatic). Five early-stage patients developed distant metastases, 60% (3/5) had detectable CTCs before radiographic detection of the metastasis. Landmark overall survival (from study enrollment) at 24 months was statistically lower in CTC-positive vs. negative early-stage UM (

Identifiants

pubmed: 31226786
pii: cancers11060856
doi: 10.3390/cancers11060856
pmc: PMC6628316
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : Skin spore Grant number 10750
Pays : United States

Références

JCO Precis Oncol. 2018 May 17;2:
pubmed: 32913999
Clin Cancer Res. 2004 Mar 1;10(5):1605-12
pubmed: 15014010
Arch Ophthalmol. 2009 Aug;127(8):989-98
pubmed: 19667335
Cancer Discov. 2016 May;6(5):479-91
pubmed: 26969689
Nat Biotechnol. 2013 Jun;31(6):539-44
pubmed: 23609047
Cancer. 2018 Jul 1;124(13):2693-2703
pubmed: 29579316
Br J Ophthalmol. 2015 Nov;99(11):1550-3
pubmed: 25904122
Science. 2013 Sep 13;341(6151):1186-8
pubmed: 24031008
Invest Ophthalmol Vis Sci. 2014 Jun 26;55(7):4395-404
pubmed: 24970258
Pigment Cell Melanoma Res. 2016 Sep;29(5):583-9
pubmed: 27390171
Int J Cancer. 2014 Mar 1;134(5):1207-13
pubmed: 23934701
Eye (Lond). 2017 Feb;31(2):241-257
pubmed: 27911450
Genome Med. 2011 May 31;3(5):31
pubmed: 21631906
Cancer. 1998 Oct 15;83(8):1664-78
pubmed: 9781962
Acta Ophthalmol. 2011 Feb;89(1):17-24
pubmed: 21272286
Clin Cancer Res. 2007 Feb 15;13(4):1171-8
pubmed: 17317826
Ophthalmology. 2011 Sep;118(9):1881-5
pubmed: 21704381

Auteurs

Kartik Anand (K)

Houston Methodist Cancer Center, Houston, TX 77030, USA. kartikanand88@gmail.com.

Jason Roszik (J)

Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA. jroszik@mdanderson.org.

Dan Gombos (D)

Department of Head and Neck Surgery, Section of Ophthalmology, UT MD Anderson Cancer Center, Houston, TX 77030, USA. dgombos@mdanderson.org.

Joshua Upshaw (J)

Department of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA. jrupshaw@mdanderson.org.

Vanessa Sarli (V)

Department of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA. vnsarli@mdanderson.org.

Salyna Meas (S)

Department of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA. smeas@mdanderson.org.

Anthony Lucci (A)

Department of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA. alucci@mdanderson.org.

Carolyn Hall (C)

Department of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA. cshall@mdanderson.org.

Sapna Patel (S)

Department of Melanoma Medical Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA. sppatel@mdanderson.org.

Classifications MeSH